MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Development"

  • 2019 International Congress

    HGprt deficiency affects early brain development in vivo in a mouse model of Lesch-Nyhan disease

    J. Witteveen, S. Loopstok, L. Luque Ballesteros, A. Boonstra, N. van Bakel, W. van Boekel, G. Martens, J. Visser, S. Kolk (Nijmegen, Netherlands)

    Objective: To determine the effects of hypoxanthine guanine phosphoribosyl transferase (HGprt) deficiency on early brain development in vivo, in a HPRT1-deficient mouse model. Background: Lesch-Nyhan…
  • 2019 International Congress

    Special features of parkinsonism with congenital anomalies of cerebral vessels

    AS. Norboboev, FAY. Odinaev, GUL. Rakhmatullaeva (Tashkent, Uzbekistan)

    Objective: To study the features of the flow of parkinsonism with congenital anomalies of cerebral vessels. Background: Analysis of the study of neurological status, data…
  • 2019 International Congress

    Evaluation of nigral neuronal apoptosis during postnatal development and adulthood of mice strains with differential sensitivity to MPTP

    Y. H, V. Dj, C. Sagar, R. Tr, P. Alladi (Bangalore, India)

    Objective: Compare nigral neurons in C57BL/6J, CD-1 and their F1 crossbreds with respect to developmental apoptosis in the nigra during postnatal and to assess MPTP-induced…
  • 2019 International Congress

    Gender-dependent improvement in the survival of Parkinson’s disease patients in Finland

    T. Kuusimäki, S. Kurki, J. Sipilä, H. Salminen-Mankonen, O. Carpén, V. Kaasinen (Turku, Finland)

    Objective: To longitudinally investigate the overall survival (OS) of a large cohort of Parkinson's disease (PD) patients. Background: While there is evidence of increasing incidence,…
  • 2019 International Congress

    Laboratory Performance of the DopaFuse® Delivery System

    R. Draper, J. Harmon, A. Heller, B. Heller, E. Heller, C. King, T. Lau, P. Plante, J. Spiridigliozzi (Austin, TX, USA)

    Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…
  • 2019 International Congress

    A Human Factors Study of the DopaFuse® Delivery System

    J. Harmon, S. Japp, C. Long, J. Spiridigliozzi, A. Heller, B. Heller, C. King, P. Plante, R. Draper, T. Lau, E. Heller (Bala Cynwyd, PA, USA)

    Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer oral LD/CD into the mouths of patients with PD. The System is…
  • 2019 International Congress

    Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?

    S. Palfi, C. Denot, A. Bousseau, JC. Corvol (Paris, France)

    Objective: Design an early CT program to detect a neuroprotective signal in PD. Background: Attempts to develop PD modifying therapies have been largely disappointing so…
  • 2019 International Congress

    5 cases Static Encephalopathy of childhood with NeuroDegeneration in Adulthood (OMIM 300894) in children

    M. Bobylova, N. Perumova, T. Prygunova, K. Mukhin (Moscow, Russian Federation)

    Objective: 5 russian female patients aged 3 to 6 years with different mutations of the WDR45 gene were examined. Background: To study the clinical picture…
  • 2018 International Congress

    Economics of Botulinum Toxin Therapy: Influence of the AbobotulinumtoxinA Package Size on the Costs of Botulinum Toxin Therapy

    F. Adib Saberi, D. Dressler (Hamburg, Germany)

    Objective: To explore whether more differentiated package sizes allow for more economic use of Dysport® in a large neurological botulinum toxin (BT) outpatient clinic (>9000…
  • 2018 International Congress

    Development of a biomarker for Parkinson’s disease by measuring alpha-synuclein oligomers in cerebrospinal fluid with ultrasonication-induced amyloid fibril formation

    K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, H. Hayakawa, T. Omichi, K. Baba, K. Konaka, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

    Objective: To establish a new technique quantifying misfolded alpha-synuclein (αSyn) oligomers in the CSF and to investigate their clinical - pathological significances in Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #28970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley